178 related articles for article (PubMed ID: 20977342)
1. Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.
Pawlowski SW; Calabrese G; Kolling GL; Platts-Mills J; Freire R; AlcantaraWarren C; Liu B; Sartor RB; Guerrant RL
J Infect Dis; 2010 Dec; 202(11):1708-12. PubMed ID: 20977342
[TBL] [Abstract][Full Text] [Related]
2. Piglet models of acute or chronic Clostridium difficile illness.
Steele J; Feng H; Parry N; Tzipori S
J Infect Dis; 2010 Feb; 201(3):428-34. PubMed ID: 20039803
[TBL] [Abstract][Full Text] [Related]
3. Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice.
Kim MN; Koh SJ; Kim JM; Im JP; Jung HC; Kim JS
World J Gastroenterol; 2014 Dec; 20(45):17084-91. PubMed ID: 25493020
[TBL] [Abstract][Full Text] [Related]
4. Immune responses to Clostridium difficile infection.
Madan R; Petri WA
Trends Mol Med; 2012 Nov; 18(11):658-66. PubMed ID: 23084763
[TBL] [Abstract][Full Text] [Related]
5. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.
Theriot CM; Koumpouras CC; Carlson PE; Bergin II; Aronoff DM; Young VB
Gut Microbes; 2011; 2(6):326-34. PubMed ID: 22198617
[TBL] [Abstract][Full Text] [Related]
6. NAP1 strain type predicts outcomes from Clostridium difficile infection.
See I; Mu Y; Cohen J; Beldavs ZG; Winston LG; Dumyati G; Holzbauer S; Dunn J; Farley MM; Lyons C; Johnston H; Phipps E; Perlmutter R; Anderson L; Gerding DN; Lessa FC
Clin Infect Dis; 2014 May; 58(10):1394-400. PubMed ID: 24604900
[TBL] [Abstract][Full Text] [Related]
7. Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile.
Viladomiu M; Hontecillas R; Pedragosa M; Carbo A; Hoops S; Michalak P; Michalak K; Guerrant RL; Roche JK; Warren CA; Bassaganya-Riera J
PLoS One; 2012; 7(10):e47525. PubMed ID: 23071818
[TBL] [Abstract][Full Text] [Related]
8. IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection.
Frisbee AL; Saleh MM; Young MK; Leslie JL; Simpson ME; Abhyankar MM; Cowardin CA; Ma JZ; Pramoonjago P; Turner SD; Liou AP; Buonomo EL; Petri WA
Nat Commun; 2019 Jun; 10(1):2712. PubMed ID: 31221971
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice.
Sadighi Akha AA; McDermott AJ; Theriot CM; Carlson PE; Frank CR; McDonald RA; Falkowski NR; Bergin IL; Young VB; Huffnagle GB
Immunology; 2015 Apr; 144(4):587-97. PubMed ID: 25327211
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis.
Vardakas KZ; Konstantelias AA; Loizidis G; Rafailidis PI; Falagas ME
Int J Infect Dis; 2012 Nov; 16(11):e768-73. PubMed ID: 22921930
[TBL] [Abstract][Full Text] [Related]
11. Teaching old mice new tricks: the utility of aged mouse models of C. difficile infection to study pathogenesis and rejuvenate immune response.
Shin JH; Pawlowski SW; Warren CA
Gut Microbes; 2021; 13(1):1966255. PubMed ID: 34432545
[TBL] [Abstract][Full Text] [Related]
12. Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease.
Spinler JK; Brown A; Ross CL; Boonma P; Conner ME; Savidge TC
Anaerobe; 2016 Aug; 40():54-7. PubMed ID: 27180007
[TBL] [Abstract][Full Text] [Related]
13. Protective role of commensals against Clostridium difficile infection via an IL-1β-mediated positive-feedback loop.
Hasegawa M; Kamada N; Jiao Y; Liu MZ; Núñez G; Inohara N
J Immunol; 2012 Sep; 189(6):3085-91. PubMed ID: 22888139
[TBL] [Abstract][Full Text] [Related]
14. Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis.
Jarchum I; Liu M; Shi C; Equinda M; Pamer EG
Infect Immun; 2012 Sep; 80(9):2989-96. PubMed ID: 22689818
[TBL] [Abstract][Full Text] [Related]
15. Tryptophan catabolism restricts IFN-γ-expressing neutrophils and Clostridium difficile immunopathology.
El-Zaatari M; Chang YM; Zhang M; Franz M; Shreiner A; McDermott AJ; van der Sluijs KF; Lutter R; Grasberger H; Kamada N; Young VB; Huffnagle GB; Kao JY
J Immunol; 2014 Jul; 193(2):807-16. PubMed ID: 24935925
[TBL] [Abstract][Full Text] [Related]
16. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile.
Nagaro KJ; Phillips ST; Cheknis AK; Sambol SP; Zukowski WE; Johnson S; Gerding DN
Antimicrob Agents Chemother; 2013 Nov; 57(11):5266-70. PubMed ID: 23939887
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis.
Jarchum I; Liu M; Lipuma L; Pamer EG
Infect Immun; 2011 Apr; 79(4):1498-503. PubMed ID: 21245274
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.
Kim HB; Zhang Q; Sun X; Beamer G; Wang Y; Tzipori S
Antimicrob Agents Chemother; 2014 Dec; 58(12):7560-4. PubMed ID: 25267665
[TBL] [Abstract][Full Text] [Related]
19. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.
Gebhart D; Lok S; Clare S; Tomas M; Stares M; Scholl D; Donskey CJ; Lawley TD; Govoni GR
mBio; 2015 Mar; 6(2):. PubMed ID: 25805733
[TBL] [Abstract][Full Text] [Related]
20. Improving the reproducibility of the NAP1/B1/027 epidemic strain R20291 in the hamster model of infection.
Kelly ML; Ng YK; Cartman ST; Collery MM; Cockayne A; Minton NP
Anaerobe; 2016 Jun; 39():51-3. PubMed ID: 26946361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
